Therapeutic peptides for the treatment of metastatic cancer

Details Therapeutic peptides for the treatment of metastatic cancer Therapeutic peptides for the treatment of metastatic cancer

A - Human Necessities

61

K

A61K 38/00 (2006.01)

Patent

CA 2601823

Interaction between MUCl and .beta.-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUCl. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.

L'interaction entre le MUCI et la .beta.-caténine peut être interrompue par l'utilisation de polypeptides ou d'anticorps qui se lient spécifiquement au site de liaison du MUCI. Cette interruption a un effet bénéfique d'inhibition, de réduction, et/ou de retardement de l'invasion et de la métastase. Des polypeptides de fusion et des anticorps sont utilisés pour obtenir un effet thérapeutique.

Affiliated with

Also associated with

Rating

Therapeutic peptides for the treatment of metastatic cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic peptides for the treatment of metastatic cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic peptides for the treatment of metastatic cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1466992